BioCurity Pharmaceuticals

BioCurity is a biopharmaceutical company developing drugs to transform radiation therapy. Our mission is to prevent certain side effects of radiation therapy for cancer patients. The side effects range from burns to the skin for breast cancer patients to pneumonia for lung cancer patients. Damage to healthy tissue of cancer patients undergoing radiation therapy is a direct cause of these side effects. The proposed drugs under development are from BioCurity’s patented technology and have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. Consistent with our preclinical studies we intend to mitigate side effects of radiation therapy without impairing the effectiveness of radiation treatment.

Our proposed drugs are intended to provide cost effective protection for millions of cancer patients undergoing radiation therapy every year from the side effects of radiation therapy.

Seven issued US patents with fully paid license for its technology in the US as well as international patents owned by the Company for our technology when patients are undergoing radiation combined with chemotherapy.

BioCurity management is focused on meeting development milestones of the proposed drug (including a growing IP portfolio) and thereby increasing the valuation of BioCurity for investors with funds that are raised.

Dr. Cheryl Baker
Director and Scientific Founder
Cheryl Baker has conducted cancer research for 20 plus years and published more than 45 peer-reviewed manuscripts, book chapters and articles. The proprietary nanoparticle technology supporting BioCurity’s mission was preclinically developed and tested by Cheryl Baker and her research and physician-scientist colleagues at an MD Anderson Cancer Center affiliate in collaboration with researchers at a State University. Cheryl works 40 hours per week for the issuer.

Sam Merchant
Chairman of the Board of Directors
Sam has 30 Years of Experience, Co-Chairman, 3rd Generation Global Family Office, Extensive Success Growing Companies Globally in Multiple Sectors including, Information-Technology, Healthcare, Bio-Technology, Pharmaceutical, R&D, Manufacturing, Distribution, Commercial Real Estate, Banking and Finance and other sectors. He has been a part of Capital Market Development for over 100 International and Domestic Companies. He works a minimum of 30 hours per week combined with Ms. Nancy Cass pursuant to the MerchantCass Advisors agreement.

Nancy Cass, Esq
Director
Nancy has 20 plus years securities law and transactional law experience with public and private emerging growth and middle market companies. Experienced in examining opportunities for financings, strategic partnerships and other transactions. Interacts with attorneys on transactions, review documents and conducts due diligence with added insight from her legal and securities training. She works a minimum of 30 hours per week combined with Mr. Sam Merchant pursuant to the MerchantCass Advisors agreement.